文献速递头颈部肿瘤放疗放疗物理与技术

碳离子推量调强放疗治疗高危鼻窦鳞癌的结局与颈淋巴结管理

Intensity-modulated radiotherapy with carbon ion boost for high-risk sinonasal squamous cell carcinoma: clinical outcomes and the management of the node-negative neck.
PubMed 文献 · Clin Transl Radiat Oncol · 2025-10-27

本研究评估了43例高危鼻窦鳞状细胞癌患者接受调强放疗(IMRT)联合碳离子推量的疗效、颈淋巴结管理策略及毒性。多数为T3-4期(83.7%)且临床淋巴结阴性(93.0%),中位随访25.1个月,12/24个月总生存率分别为93.0%/89.3%,局部无进展生存率为88.4%/79.0%,3级急性和晚期毒性分别为9.3%和4.7%。结论认为该方案疗效可观且毒性可接受,淋巴结阴性颈部的管理高度个体化。

要点

  • IMRT联合碳离子推量治疗高危鼻窦鳞癌12/24个月OS为93.0%/89.3%。
  • 局部失败是主要复发模式,占复发患者的63.6%。
  • 3级急性与晚期毒性分别为9.3%和4.7%,无4级毒性。

核心结论

  • IMRT联合碳离子推量在高危鼻窦鳞癌中提供了有前景的总生存和局部控制。
  • 淋巴结阴性颈部的管理高度个体化,毒性可接受且可能通过个体化颈部治疗进一步降低。

研究设计与样本

  • 回顾性评估2011至2019年间43例接受IMRT联合碳离子推量的鼻窦鳞癌患者。
  • 随访遵循头颈癌指南,评估患者与肿瘤特征、治疗结局及按CTCAE v5.0的毒性,使用R 4.1.0进行统计分析。

主要发现

  • 中位年龄64岁(范围19-83),T3-4期占83.7%(36例),临床淋巴结阴性占93.0%(40例)。
  • 主要方案为碳离子推量24 Gy(RBE)分8次,随后IMRT 50 Gy分25次。
  • 术后放疗25例(58.1%),根治性放疗18例(41.9%)。
  • 11例(25.6%)出现复发,其中局部失败7例(63.6%)。
  • 12/24个月OS为93.0%/89.3%,L-PFS为88.4%/79.0%;3级急性与晚期毒性分别为9.3%和4.7%,无4级毒性。

关键数值与推荐

  • 碳离子推量24 Gy(RBE)分8次,随后IMRT 50 Gy分25次为主要放疗方案。
  • 颈部淋巴结清扫10例(23.3%),均未发现淋巴结转移;共应用22种不同的颈部淋巴结治疗策略。
  • 12/24个月OS为93.0%/89.3%,L-PFS为88.4%/79.0%。
  • 3级急性毒性和晚期毒性分别为9.3%和4.7%,无4级毒性;每位患者平均1-2级毒性数量为急性4.8、晚期2.4。

临床怎么用

  • 对于高危鼻窦鳞癌,可考虑IMRT联合碳离子推量以改善局部控制。
  • 临床淋巴结阴性颈部可个体化选择治疗策略,避免不必要的颈清扫。
  • 治疗毒性总体可接受,但仍需关注急性和晚期3级毒性。

局限性

  • 回顾性研究,样本量较小(43例)。
  • 颈部淋巴结治疗策略异质性大(22种),难以比较不同策略的优劣。
  • 中位随访时间较短(OS随访25.1个月),长期结局需进一步观察。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Local control of high-risk sinonasal squamous cell carcinoma (SCC) remains challenging and often involves significant morbidity. Management of the node-negative neck is still debated. This study evaluated treatment outcomes, neck management strategies, and toxicity rates in patients treated with intensity-modulated radiotherapy (IMRT) combined with a carbon ion boost. METHODS: We evaluated 43 patients with sinonasal SCC treated with IMRT and carbon ion boost between 2011 and 2019. Follow-up followed head and neck cancer guidelines. Patient and tumor characteristics, treatment outcomes, and toxicity (per CTCAE v5.0) were assessed. Statistical analysis was performed using R version 4.1.0. RESULTS: Median age was 64 years (range 19-83). Most patients had T3-4 tumors (n = 36; 83.7 %) and were clinically node-negative (n = 40; 93.0 %). The predominant regimen was 24 Gy (RBE) carbon ion boost in 8 fractions, followed by 50 Gy IMRT in 25 fractions. Postoperative RT was delivered to 25 patients (58.1 %), while 18 (41.9 %) received definitive RT. Elective or therapeutic neck dissection was performed in 10 patients (23.3 %), none showing lymph node metastases. In total, 22 distinct cervical lymph node treatment strategies were applied. Median follow-up for overall survival (OS) was 25.1 months. Tumor recurrence occurred in 11 patients (25.6 %), primarily due to local failure (n = 7; 63.6 %). OS and local progression-free survival (L-PFS) at 12/24 months were 93.0 %/89.3 % and 88.4 %/79.0 %, respectively. Grade III acute and late toxicity occurred in 9.3 % and 4.7 % of patients, respectively. No grade IV toxicity was reported. Mean numbers of grade I-II toxicities per patient were 4.8 (acute) and 2.4 (late). CONCLUSION: IMRT with carbon ion boost provides promising OS and local control in high-risk sinonasal SCC. The management of the node-negative-neck was highly individualized. Toxicity was acceptable and may be further reduced by tailoring cervical lymph node treatment in selected patients.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Bauer L, Weusthof K, Regnery S, et al. Intensity-modulated radiotherapy with carbon ion boost for high-risk sinonasal squamous cell carcinoma: clinical outcomes and the management of the node-negative neck. Clin Transl Radiat Oncol. 2025. PMID: 41281630. doi:10.1016/j.ctro.2025.101064

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。